Application Cases

• Heterogeneity of MAIT cells in the HCC tumor microenvironment

  Professor Tim F. Greten, National Institutes of Health, National Cancer Institute Center for Cancer Research, and his team analyzed the heterogeneity and dysfunction of MAIT cells in HCC, as well as the defects in their ability to infiltrate liver tumors, through the coupling of multi-omics techniques (scRNA-seq, CODEX, FACS). Co-localization in the adjacent liver and the interaction of vacuolating CSF1R+PD-L1+ tumor-associated macrophages (TAMs) with MAIT cells were identified as key regulators of MAIT cell dysfunction. Perturbation of this cell-cell interaction reactivated MAIT cell cytotoxicity in in vitro co-culture studies using patient samples and mouse models. These studies suggest that aPD-1/aPD-L1 treatment targets MAIT cells in HCC patients.

  
• Strong Combination of Null Spin Visium and CODEX Reveals Glioblastoma Has a Multilayered Structure

  The development of spatial multi-omics has enabled researchers to perform fine-grained in situ spatial mapping of cell types and cell states. on April 22, 2024, Prof. Itay Tirosh's team from the Weizmann Institute of Science, Israel, carried out a comprehensive and In-depth spatial in situ analysis revealed that GBM consists of structured and disordered regions; the structured regions contain five levels of organization associated with hypoxia; and features of the regions not identified by classical histopathology were discovered.

  
• Nature|Single-cell and spatial genomics combine to produce the largest-ever human breast cell atlas

  The first single-cell and spatial genomics combined mapping of human breast cells provides a comprehensive reference for the study of breast biology, development, and diseases such as breast cancer by improving the understanding of epithelial and non-epithelial cell types in human breast tissue.

  
• Cell | TCF4-dependent gene regulatory network helps melanoma resist immunotherapy

  The number of MES melanoma cells increased significantly in patients after ICB treatment, and TCF4 is a key factor in the associated regulatory network. Targeting TCF4 increased the sensitivity and immunogenicity of melanoma cells to targeted therapy and ICB treatment. This study reveals a TCF4-dependent gene regulatory network that plays an important role in melanoma resistance to targeted therapy and ICB treatment.